UBS Lowers Apogee Therapeutics Rating to Hold

UBS analyst Michael Yee has downgraded Apogee Therapeutics, Inc. (NasdaqGM: APGE) to a hold rating with a new price target of $135.11. This change was announced on June 23, 2026, as the stock traded around $132.55.

Other Institutional Activity in Apogee Therapeutics

Several institutional investors have also made moves in Apogee Therapeutics. T. Rowe Price Investment Management, Inc. increased its holdings by 7,568,528 shares to a total of 10,300,984 shares, valued at approximately $867.03 million. FMR LLC grew its position by 1,037,253 shares, ending with 9,262,291 shares worth around $779.61 million. Meanwhile, Venrock Adviser, LLC maintained its holdings at 8,493,321 shares, with no change. Wellington Management Group LLP reduced its stake by 370,882 shares to 4,375,703 shares, valued at $368.30 million. BlackRock, Inc. added 301,657 shares, bringing its total to 4,085,651 shares, valued at $343.89 million.

Apogee Therapeutics, Inc. Stock Down 1.7%

Shares of Apogee Therapeutics traded near $132.55 on Tuesday. The company has a market capitalization of about $9.99 billion. It is not currently profitable, with a forward P/E ratio of -25.52. The stock's beta is 0.619, indicating lower volatility compared to the market. Apogee's 52-week range is between $34.34 and $133.00, with a 50-day moving average of $84.76 and a 200-day moving average of $69.38. The company boasts a strong financial position with a current ratio of 32.59 and a quick ratio of 32.39.

Insider Buying and Selling at Apogee Therapeutics, Inc.

In recent insider activity, CEO Dr. Michael Thomas Henderson sold 20,000 shares on June 10, 2026, at an average price of $83.38 as part of a planned transaction. On June 9, 2026, several insiders, including Mark McKenna, William Jones Jr., and others, acquired 7,657 shares each at undisclosed prices.

Analysts Set New Price Targets

On June 23, 2026, UBS downgraded Apogee Therapeutics to a hold rating with a $135.11 price target. The day before, Canaccord Genuity also downgraded the stock to hold with the same target. RBC Capital maintained its hold rating with a $97.00 target on June 8, 2026. The consensus among analysts is a strong buy, with a mean target price of $119.50, based on 16 analyst opinions.

About Apogee Therapeutics

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company based in Waltham, Massachusetts. It focuses on developing novel biologics for treating inflammatory and immunology conditions such as atopic dermatitis, asthma, and eosinophilic esophagitis. The company is led by CEO Dr. Michael Thomas Henderson and employs 261 people. Apogee's pipeline includes Zumilokibart (APG777) and other monoclonal antibodies in various stages of clinical trials.

Bottom Line

UBS's recent downgrade of Apogee Therapeutics to a hold rating reflects a more cautious stance on the stock. Investors are keeping an eye on the company's promising pipeline in the biotechnology sector. It's important to note that analyst ratings and institutional holdings can change, and this report is based on data available as of June 2026.